No profile data available.
Intellipharmaceutics International Inc. (IPCIQ) is a healthcare company in the multi-therapeutic drug manufacturing industry, based in Toronto, Canada, with about 11 full-time employees.
It reported revenue of $65,728 for fiscal year 2022, and net income of -$2.89 million. In Q3 2023 (the quarter ended August 31, 2023) revenue was $68,718, up 260.4% from a year before. Its market capitalization was $4.96 million as of October 8, 2026.
Figures from company filings and market data; latest fiscal year ended November 30, 2022; market data as of October 8, 2026.
, a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States.
Intellipharmaceutics International reported $65,728 in revenue for fiscal year 2022. In Q3 2023 revenue was $68,718.
$4.96 million as of October 8, 2026.
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Revelation Biosciences, Inc. (REVB), Can-Fite BioPharma Ltd. (CANF), LianBio (LIANY), Oncology Pharma Inc. (ONPH).